Axsome Therapeutics, Inc. (AXSM)
206.20
-0.96
(-0.46%)
USD |
NASDAQ |
Aug 27, 16:00
206.20
0.00 (0.00%)
After-Hours: 16:47
Axsome Therapeutics Shareholders Equity (Quarterly) : 83.30M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.30M |
| March 31, 2026 | 54.59M |
| December 31, 2025 | 88.30M |
| September 30, 2025 | 73.73M |
| June 30, 2025 | 73.08M |
| March 31, 2025 | 53.20M |
| December 31, 2024 | 57.02M |
| September 30, 2024 | 92.90M |
| June 30, 2024 | 102.85M |
| March 31, 2024 | 144.04M |
| December 31, 2023 | 190.98M |
| September 30, 2023 | 269.51M |
| June 30, 2023 | 278.80M |
| March 31, 2023 | 111.81M |
| December 31, 2022 | 109.56M |
| September 30, 2022 | 157.36M |
| June 30, 2022 | 15.20M |
| March 31, 2022 | 14.70M |
| December 31, 2021 | 15.63M |
| September 30, 2021 | 42.72M |
| June 30, 2021 | 71.44M |
| March 31, 2021 | 96.29M |
| Date | Value |
|---|---|
| December 31, 2020 | 113.79M |
| September 30, 2020 | 135.26M |
| June 30, 2020 | 154.24M |
| March 31, 2020 | 156.16M |
| December 31, 2019 | 178.72M |
| September 30, 2019 | 6.823M |
| June 30, 2019 | 24.28M |
| March 31, 2019 | 17.37M |
| December 31, 2018 | 0.9379M |
| September 30, 2018 | 0.7428M |
| June 30, 2018 | 7.009M |
| March 31, 2018 | 12.59M |
| December 31, 2017 | 16.72M |
| September 30, 2017 | 16.84M |
| June 30, 2017 | 22.75M |
| March 31, 2017 | 29.28M |
| December 31, 2016 | 21.57M |
| September 30, 2016 | 28.18M |
| June 30, 2016 | 34.90M |
| March 31, 2016 | 41.23M |
| December 31, 2015 | 46.44M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Eli Lilly & Co. | 33.88B |
| Liquidia Corp. | 195.11M |
| Filana Therapeutics, Inc. | 63.61M |
| CorMedix, Inc. | 460.83M |
| Eloxx Pharmaceuticals, Inc. | 46.42M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 761.45M |
| Total Liabilities (Quarterly) | 678.14M |
| Debt to Equity Ratio | 2.697 |
| Current Ratio | 1.426 |
| Net Debt Paydown Yield | -0.02% |